KEYNOTE-667: PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY

被引：0
|
作者：
Vinti, Luciana [1 ]
Daw, Stephen [2 ]
Alvarez, Constantino Sabado [3 ]
Fagioli, Franca [4 ]
Beishuizen, Auke [5 ]
Michel, Gerard [6 ]
Moleti, Maria Luisa [7 ]
Cepelova, Michaela [8 ]
Thorwarth, Anne [9 ]
Rigaud, Charlotte [10 ]
De Sabando, Diego Plaza Lopez [11 ]
Parker, Judith Landman [12 ]
Zhu, Ying [13 ]
Pillai, Pallavi [13 ]
Nahar, Akash [13 ]
Mauz-Koerholz, Christine [14 ,15 ]
机构：
[1] IRCCS Osped Pediatrico Bambino Gesu, Pediat Hematol & Oncol, Rome, Italy
[2] Univ Coll London Hosp NHS Fdn Trust, Pediat & Hematol Oncol, London, England
[3] Hosp Univ Vall Hebron, Pediat Oncol, Barcelona, Spain
[4] Osped Infantile Regina Margherita, Pathol & Child Care, Turin, Italy
[5] Princess Maxima Centrum, Hematol Malignancies, Utrecht, Netherlands
[6] CHU Marseille, Hop Timone Enfants, Pediat & Pediat Hematol, Marseille, France
[7] Univ Roma La Sapienza, Pediat Hematol & Oncol, Rome, Italy
[8] Fak Nemocnice Motole, Pediat Hematol & Oncol, Prague, Czech Republic
[9] Charite Univ Med Berlin, Campus Virchow Klinikum, Pediat Oncol & Hematol, Berlin, Germany
[10] Gustave Roussy Canc Campus, Pediat Hematol & Oncol, Villejuif, France
[11] Hosp Univ La Paz, Pediat Hematol & Oncol, Madrid, Spain
[12] Hop Enfants Armand Trousseau, Pediat, Paris, France
[13] Merck Co Inc, Med Oncol, Kenilworth, NJ USA
[14] Justus Liebig Univ Giessen, Giessen, Germany
[15] Martin Luther Univ Halle Wittenberg, Fac Med, Pediat Hematol & Oncol, Halle, Germany
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O046
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Exposure-response and age subgroup analyses to support body-weight (BW) dosing of brentuximab vedotin (BV) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults (aged 2-21 years [y]): A randomized children's oncology group phase 3 trial (AHOD1331)
    Zhang, Zufei
    Zhang, Daping
    Guo, Wenchuan
    Fenton, Keenan
    Narayanan, Sujata
    Jain, Shweta
    Jiang, Joy
    Castellino, Sharon M.
    Kelly, Kara M.
    Cole, Peter D.
    Keller, Frank G.
    Garg, Amit
    Chia, Yen Lin
    CANCER RESEARCH, 2023, 83 (07)
  • [42] Nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from Cohort D of the phase 2 CheckMate 205 study
    Engert, A.
    Domingo Domenech, E.
    Rueda, A.
    Armand, P.
    Trneny, M.
    Feldman, T.
    Ansell, S.
    Provencio, M.
    Jaeger, U.
    Cohen, J. B.
    Savage, K. J.
    Willenbacher, W.
    Sacchi, M.
    Sumbul, A.
    Ramchandren, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 273 - 273
  • [43] Nivolumab, Brentuximab Vedotin, and Bendamustine as Response-Adapted Treatment for Relapsed or Refractory Hodgkin Lymphoma in Children, Adolescents and Young Adults: Results from the Standard-Risk Cohort of the Phase 2 Checkmate 744 Study
    Harker-Murray, P.
    Leblanc, T.
    Mascarin, M.
    Mauz-Koerholz, C.
    Michel, G.
    Cooper, S.
    Beishuizen, A.
    Leger, K.
    Garaventa, A.
    Buffardi, S.
    Brugieres, L.
    Kelly, K.
    Cole, P.
    Drachtman, R.
    Galderisi, F.
    Sacchi, M.
    Francis, S.
    Daw, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 89 - 90
  • [44] Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced stage Hodgkin lymphoma treated with ABVD chemotherapy: a report from the Indian pediatric oncology group study InPOG-HL-15-01
    Jain, Sandeep
    Bakhshi, Sameer
    Seth, Rachna
    Verma, Nishant
    Singh, Manisha
    Mahajan, Amita
    Radhakrishnan, Venkatraman
    Mandal, Piali
    Arora, Ramandeep
    Dinand, Veronique
    Kalra, Manas
    Sharma, Anurag
    Taluja, Ankit
    Thulkar, Sanjay
    Biswas, Ahitagni
    Chandra, Jagdish
    LEUKEMIA & LYMPHOMA, 2022, 63 (05) : 1111 - 1118
  • [45] Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
    Katz, Deborah A.
    Chu, Michael P.
    David, Kevin A.
    Thieblemont, Catherine
    Morley, Nicholas J.
    Khan, Sharif S.
    Chen, Yuqi
    Kalabus, James
    Morris, Joan
    Anderson, Abraham
    Avilion, Ariel A.
    Gonzalez-Barca, Eva
    BLOOD, 2019, 134
  • [46] Nivolumab (nivo) and brentuximab vedotin (BV)-based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis of the R2 cohort of the phase 2 CheckMate 744 study
    Mauz-Koerholz, C.
    Cole, P. D.
    Mascarin, M.
    Michel, G.
    Cooper, S.
    Beishuizen, A.
    Leger, K. J.
    Amoroso, L.
    Buffardi, S.
    Rigaud, C.
    Puhlmann, M.
    Francis, S.
    Sacchi, M.
    Drachtman, R. A.
    Harker-Murray, P.
    Leblanc, T.
    Daw, S.
    Kelly, K. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 89 - 90
  • [47] Nivolumab and Brentuximab Vedotin (BV)-Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study
    Cole, Peter D.
    Mauz-Koerholz, Christine
    Mascarin, Maurizio
    Michel, Gerard
    Cooper, Stacy
    Beishuizen, Auke
    Leger, Kasey J.
    Amoroso, Loredana
    Buffardi, Salvatore
    Rigaud, Charlotte
    Puhlmann, Markus
    Francis, Stephen
    Sacchi, Mariana
    Drachtman, Richard A.
    Harker-Murray, Paul
    Leblanc, Thierry
    Daw, Stephen
    Kelly, Kara M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S245 - S246
  • [48] Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A plus AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)
    Franklin, Anna
    Zecca, Marco
    Fagioli, Franca
    Luisi, Flavio Augusto
    Song, Gregory
    Suri, Ajit
    Leonard, E. Jane
    Locatelli, Franco
    BLOOD, 2018, 132
  • [49] Biomarkers associated with complete metabolic response (CMR) to nivolumab and brentuximab vedotin (nivo plus BV) for the treatment of children, adolescents, and young adults (CAYA) with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) in the CheckMate 744 study
    Garnett-Benson, Charlie
    Ammar, Ron
    Crowe, Russell
    Francis, Stephen
    Ansari, Sahar
    Akyol, Alev
    CANCER RESEARCH, 2022, 82 (12)
  • [50] Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).
    Furman, Wayne Lee
    Shulkin, Barry L.
    Federico, Sara Michele
    McCarville, Mary B.
    Davidoff, Andrew M.
    Krasin, Matthew J.
    Wu, Jianrong
    Brennan, Rachel Christine
    Bishop, Michael William
    Helmig, Sara E.
    Navid, Fariba
    Santana, Victor M.
    Anthony, Gwendolyn
    Hank, Jacquelyn A.
    Gillies, Stephen D.
    Sonde, Paul M.
    Leung, Wing H.
    Pappo, Alberto S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345